A piece in Alzforum highlights two new therapeutics that degrade tau aggregates and improve symptoms of neurodegeneration in mice. The technology has been developed by Leo James’ group, in the LMB’s PNAC Division, and Will McEwan’s group at the UK Dementia Research Institute at the University of Cambridge. More…
Home > LMB In The News > Targeting Intracellular Tau Aggregates for Destruction